Lloyd Price
DECEMBER 2, 2024
In 2025, HealthTech valuations are expected to continue their upward trajectory, driven by several key factors: 1. Technological Advancements: AI and Machine Learning: AI-powered diagnostics, drug discovery, and personalised medicine are revolutionising healthcare.
Lloyd Price
NOVEMBER 16, 2024
Exec Summary: Merative, formerly known as IBM Watson Health, is gearing up to introduce a range of new products in 2025. Clinical Development: Clinical Trial Matching: Matches patients to appropriate clinical trials. Real-World Evidence: Leverages real-world data to inform clinical decision-making and drug development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Lloyd Price
NOVEMBER 8, 2024
Exec Summary: The HealthTech sector is poised for significant M&A activity in 2025, driven by several key trends: Digital Health Solutions: The increasing demand for digital health solutions to improve healthcare accessibility and efficiency will drive acquisitions of innovative startups and established players in this space.
Lloyd Price
DECEMBER 2, 2024
The wound care market is a dynamic and rapidly evolving sector, and 2025 is shaping up to be a pivotal year for innovation and growth in this field. The wound care market is poised for significant growth in 2025 and beyond. These grafts are made from a patient's own cells, which reduces the risk of rejection.
Digital Health Global
NOVEMBER 30, 2023
Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drug development. in 2020, with projections suggesting up to 70% of clinical trials incorporating wearable sensors by 2025.
Lloyd Price
OCTOBER 9, 2024
Visit www.nelsonadvisors.co.uk #HealthTech #DigitalHealth #HealthIT #NelsonAdvisors #Mergers #Acquisitions #Growth #Strategy Neuroscience innovation primed for mainstream growth in 2025 2025 is poised to be a pivotal year for neuroscience, with groundbreaking advancements poised to enter the mainstream.
Lloyd Price
JUNE 4, 2018
CVC’s recent acquisition of the women’s health division of the Israeli drug developer Teva for $800m created a company dedicated to contraception, fertility, menopause and osteoporosis. Recent analysis from Frost and Sullivan shows this market to be worth up to $50bn by 2025.
Expert insights. Personalized for you.
64 
Let's personalize your content